http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cadrenal+Therapeutics%2C++++For%3A+Jun+30/26921922.html si-local-file:///var/storage/secattach/20260813/26921922.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cadrenal+Therapeutics%2C++++For%3A+Jun+30/26921922.html Thu, 13 Aug 2026 16:32:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cadrenal+Therapeutics%2C++++For%3A+Jun+30/26921922.html si-local-file:///var/storage/secattach/20260813/26921922.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cadrenal+Therapeutics%2C++++For%3A+Jun+30/26921922.html Thu, 13 Aug 2026 16:32:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Aug+13/26921849.html si-local-file:///var/storage/secattach/20260813/26921849.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Aug+13/26921849.html Thu, 13 Aug 2026 16:31:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Aug+13/26921849.html si-local-file:///var/storage/secattach/20260813/26921849.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Aug+13/26921849.html Thu, 13 Aug 2026 16:31:00 -0400 CVKD O.54961393 http://www.streetinsider.com/Earnings/Cadrenal+Therapeutics%2C+Inc.+%28CVKD%29+Tops+Q2+EPS+by+27c/26921378.html <p>Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.14), $0.27 better than the analyst estimate of ($1.41). </p><p>For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) <a href="http://www.streetinsider.com/ec_earnings.php?q=CVKD">click here</a>.</p> http://www.streetinsider.com/Earnings/Cadrenal+Therapeutics%2C+Inc.+%28CVKD%29+Tops+Q2+EPS+by+27c/26921378.html Thu, 13 Aug 2026 16:17:03 -0400 CVKD http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html <p>PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.</p> <p>&quot;The second quarter and subsequent weeks marked an important milestone for Cadrenal,&quot; said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. &quot;Our objective is to http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Reports+Second+Quarter+2026+Financial+Results%3B+Provides+a+Corporate+Update+on+the+Cardiac+Acute+Critical+Care+Franchise+and+the+Strategic+Partnering+Process/26921291.html Thu, 13 Aug 2026 16:15:00 -0400 A.06822034 CVKD O.20026344 O.54961393 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cadrenal+Therapeutics%2C+++++++++++++++++Filed+by%3A+PNC+FINANCIAL+SERVICES+GROUP%2C+INC./26887833.html si-local-file:///var/storage/secattach/20260807/26887833.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cadrenal+Therapeutics%2C+++++++++++++++++Filed+by%3A+PNC+FINANCIAL+SERVICES+GROUP%2C+INC./26887833.html Fri, 07 Aug 2026 08:11:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cadrenal+Therapeutics%2C+++++++++++++++++Filed+by%3A+PNC+FINANCIAL+SERVICES+GROUP%2C+INC./26887833.html si-local-file:///var/storage/secattach/20260807/26887833.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cadrenal+Therapeutics%2C+++++++++++++++++Filed+by%3A+PNC+FINANCIAL+SERVICES+GROUP%2C+INC./26887833.html Fri, 07 Aug 2026 08:11:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cadrenal+Therapeutics%2C+++++++++++++++/26859267.html si-local-file:///var/storage/secattach/20260803/26859267.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cadrenal+Therapeutics%2C+++++++++++++++/26859267.html Mon, 03 Aug 2026 17:12:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cadrenal+Therapeutics%2C+++++++++++++++/26859267.html si-local-file:///var/storage/secattach/20260803/26859267.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cadrenal+Therapeutics%2C+++++++++++++++/26859267.html Mon, 03 Aug 2026 17:12:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Cadrenal+Therapeutics%2C++++For%3A+Dec+31/26859250.html si-local-file:///var/storage/secattach/20260803/26859250.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Cadrenal+Therapeutics%2C++++For%3A+Dec+31/26859250.html Mon, 03 Aug 2026 17:11:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Cadrenal+Therapeutics%2C++++For%3A+Dec+31/26859250.html si-local-file:///var/storage/secattach/20260803/26859250.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Cadrenal+Therapeutics%2C++++For%3A+Dec+31/26859250.html Mon, 03 Aug 2026 17:11:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Cadrenal+Therapeutics%2C++++For%3A+Sep+24/26859229.html si-local-file:///var/storage/secattach/20260803/26859229.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Cadrenal+Therapeutics%2C++++For%3A+Sep+24/26859229.html Mon, 03 Aug 2026 17:10:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Cadrenal+Therapeutics%2C++++For%3A+Sep+24/26859229.html si-local-file:///var/storage/secattach/20260803/26859229.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Cadrenal+Therapeutics%2C++++For%3A+Sep+24/26859229.html Mon, 03 Aug 2026 17:10:00 -0400 CVKD O.54961393 http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html <p>Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced an expansion of its development strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), following a competitor's Phase 3 trial discontinuation in the CSA-AKI space.</p> <p>The company said the competitor's trial was halted for lack of efficacy, which it cited as context for positioning CAD-1005 in the CSA-AKI market, which it estimates at over $1 billion in the U.S. CAD-1005 works through 12-lipoxygenase (12-LOX) inhibition, a mechanism the company says targets platelet hyperactivation and inflammation-driven injury.</p> <p>Phase 2 data for CAD-1005 were presented at the International Society on Thrombosis and http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html Mon, 03 Aug 2026 08:30:39 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html <p>Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced an expansion of its development strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), following a competitor's Phase 3 trial discontinuation in the CSA-AKI space.</p> <p>The company said the competitor's trial was halted for lack of efficacy, which it cited as context for positioning CAD-1005 in the CSA-AKI market, which it estimates at over $1 billion in the U.S. CAD-1005 works through 12-lipoxygenase (12-LOX) inhibition, a mechanism the company says targets platelet hyperactivation and inflammation-driven injury.</p> <p>Phase 2 data for CAD-1005 were presented at the International Society on Thrombosis and http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html Mon, 03 Aug 2026 08:30:39 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html <p>Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced an expansion of its development strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), following a competitor's Phase 3 trial discontinuation in the CSA-AKI space.</p> <p>The company said the competitor's trial was halted for lack of efficacy, which it cited as context for positioning CAD-1005 in the CSA-AKI market, which it estimates at over $1 billion in the U.S. CAD-1005 works through 12-lipoxygenase (12-LOX) inhibition, a mechanism the company says targets platelet hyperactivation and inflammation-driven injury.</p> <p>Phase 2 data for CAD-1005 were presented at the International Society on Thrombosis and http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html Mon, 03 Aug 2026 08:30:39 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html <p>Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced an expansion of its development strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), following a competitor's Phase 3 trial discontinuation in the CSA-AKI space.</p> <p>The company said the competitor's trial was halted for lack of efficacy, which it cited as context for positioning CAD-1005 in the CSA-AKI market, which it estimates at over $1 billion in the U.S. CAD-1005 works through 12-lipoxygenase (12-LOX) inhibition, a mechanism the company says targets platelet hyperactivation and inflammation-driven injury.</p> <p>Phase 2 data for CAD-1005 were presented at the International Society on Thrombosis and http://www.streetinsider.com/FDA/Cadrenal+expands+CAD-1005+strategy+after+rival%27s+Phase+3+failure/26854492.html Mon, 03 Aug 2026 08:30:39 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393